BRIEF—Amarin inks Vazkepa distribution deal with CSL Seqirus

New Jersey, USA-based Amarin has inked a deal with CSL Seqirus for the licensing and distribution of Vazkepa (icosapent ethyl).

The heart med, which is marketed in the USA as Vascepa, was launched in Europe in late 2021.

The commercialization agreement covers Australia, the home of parent company CSL Limited, and nearby New Zealand.

Under the terms of the deal, CSL will negotiate for a pricing and reimbursement agreement before going on to commercialize the product across the two countries.

Amarin will receive an undisclosed upfront payment and be eligible for milestone payments of up to $12 million, and will supply finished product to CSL Seqirus for a profit.